Rapidly advancing pipeline



» EGFR+ NSCLC ³				
BLU-222: CDK2				
» CDK2-vulnerable cancers				
ancer immunotherapy				
BLU-852: MAP4K1				
» Advanced cancers ⁹				
esearch				
Multiple undisclosed research programs				
ongoing or completed planned			Updated as of August 17, 2022	2.
 ongoing or completed planned ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib an ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT[®] for the treatment of adult patileukemia, after at least one systemic therapy. 	h an associated hematologic	c neoplasm and mast cell	and Taiwan. Ieukemia. Received marketing	2.
¹ CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib an ² Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult pati	h an associated hematologic	c neoplasm and mast cell	and Taiwan. Ieukemia. Received marketing	2.
¹ CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib an ² Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT [®] for the treatment of adult pati- leukemia, after at least one systemic therapy.	n an associated hematologic ients with aggressive SM, SN DGFRA exon 18 mutation, inc	e neoplasm and mast cell A with an associated hem cluding PDGFRA D842V m	and Taiwan. leukemia. Received marketing natological neoplasm or mast cell nutations. Received conditional	2.
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib an ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patieleukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD 	n an associated hematologic ients with aggressive SM, SN OGFRA exon 18 mutation, inc of adults with unresectable o	e neoplasm and mast cell A with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori	and Taiwan. leukemia. Received marketing natological neoplasm or mast cell nutations. Received conditional ng the PDGFRA D842V mutation.	2.
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib at ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patileukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of s⁵In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and one and the section of the treatment of adults. 	n an associated hematologic ients with aggressive SM, SM OGFRA exon 18 mutation, inc of adults with unresectable o commercialize pralsetinib in	c neoplasm and mast cell A with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori the U.S., and Roche has e roval may be contingent c	and Taiwan. leukemia. Received marketing natological neoplasm or mast cell nutations. Received conditional ing the PDGFRA D842V mutation. exclusive rights to develop and	2.
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib at ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patileukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of some and the brand name AYVAKYT® for the treatment of a provide the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment or some arketing authorization in the European Union under the brand name AYVAKYT® for the treatment or some arketing authorization in the European Union under the brand name AYVAKYT® for the treatment or some arketing authorization in the European Union under the brand name AYVAKYT® for the treatment or some arketing authorization in the U.S., excluding the CStone territory. ⁶Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position provide the U.S. for the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment of adults with metastatic RET fusion-position and the treatment adults wi	n an associated hematologic ients with aggressive SM, SM OGFRA exon 18 mutation, inc of adults with unresectable o commercialize pralsetinib in sitive NSCLC. Continued appr positive NSCLC not previous	c neoplasm and mast cell If with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori the U.S., and Roche has e roval may be contingent c sly treated with a RET inhi	and Taiwan. leukemia. Received marketing hatological neoplasm or mast cell nutations. Received conditional ing the PDGFRA D842V mutation. exclusive rights to develop and on a confirmatory trial. Received bitor.	
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib at ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patileukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of ⁵In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory. ⁶Received accelerated approval in the U.S. for the treatment of adults with advanced RET fusion-pos conditional marketing authorization in Europe for the treatment of adults with advanced or metastatic F 	n an associated hematologic ients with aggressive SM, SM OGFRA exon 18 mutation, inc of adults with unresectable o commercialize pralsetinib in sitive NSCLC. Continued appr positive NSCLC not previous RET-mutant medullary thyroi	e neoplasm and mast cell If with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori the U.S., and Roche has e roval may be contingent c sly treated with a RET inhi id cancer and RET fusion-	and Taiwan. leukemia. Received marketing hatological neoplasm or mast cell nutations. Received conditional ing the PDGFRA D842V mutation. exclusive rights to develop and on a confirmatory trial. Received bitor.	
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib at ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patileukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of some arketing authorization in the European Union under the brand name AYVAKYT® for the treatment of ⁵In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory. ⁶Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-pos conditional marketing authorization in Europe for the treatment of adults with advanced or metastatic F approval may be contingent on confirmatory trials. 	n an associated hematologic ients with aggressive SM, SM OGFRA exon 18 mutation, inc of adults with unresectable o commercialize pralsetinib in sitive NSCLC. Continued appr positive NSCLC not previous RET-mutant medullary thyroi Hong Kong, Macau and Taiv	e neoplasm and mast cell A with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori the U.S., and Roche has a roval may be contingent of sly treated with a RET inhi id cancer and RET fusion- wan.	and Taiwan. leukemia. Received marketing hatological neoplasm or mast cell nutations. Received conditional ing the PDGFRA D842V mutation. exclusive rights to develop and on a confirmatory trial. Received bitor. -positive thyroid cancer. Continued	1
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib an ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patileukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of some arketing authorization in the European Union under the brand name AYVAKYT® for the treatment of some commercialize pralsetinib outside the U.S., excluding the CStone territory. ⁶Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-post conditional marketing authorization in Europe for the treatment of adults with advanced or metastatic F approval may be contingent on confirmatory trials. ⁸Zai Lab has exclusive rights to develop and commercialize BLU-701 and BLU-945 in Mainland China, ⁹In collaboration with Roche. For one of the programs, Blueprint Medicines has U.S. commercial rights 	n an associated hematologic ients with aggressive SM, SM OGFRA exon 18 mutation, inc of adults with unresectable o commercialize pralsetinib in sitive NSCLC. Continued appr positive NSCLC not previous RET-mutant medullary thyroi Hong Kong, Macau and Taiv	e neoplasm and mast cell A with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori the U.S., and Roche has a roval may be contingent of sly treated with a RET inhi id cancer and RET fusion- wan.	and Taiwan. leukemia. Received marketing hatological neoplasm or mast cell nutations. Received conditional ing the PDGFRA D842V mutation. exclusive rights to develop and on a confirmatory trial. Received bitor. -positive thyroid cancer. Continued	1
 ¹CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib an ²Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patileukemia, after at least one systemic therapy. ³Unresectable or metastatic disease. ⁴Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PD marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of ⁵In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib outside the U.S. for the treatment of adults with metastatic RET fusion-pos conditional marketing authorization in Europe for the treatment of adults with advanced RET fusion-pos conditional marketing authorization in Europe for the treatment of adults with advanced or metastatic F approval may be contingent on confirmatory trials. ⁸Zai Lab has exclusive rights to develop and commercialize BLU-701 and BLU-945 in Mainland China, ⁹In collaboration with Roche. For one of the programs, Blueprint Medicines has U.S. commercial rights worldwide commercialization rights. 	h an associated hematologic ients with aggressive SM, SM OGFRA exon 18 mutation, inc of adults with unresectable of commercialize pralsetinib in sitive NSCLC. Continued appr positive NSCLC not previous RET-mutant medullary thyroi Hong Kong, Macau and Taiv s and Roche has ex-U.S. con	e neoplasm and mast cell A with an associated hem cluding PDGFRA D842V m r metastatic GIST harbori the U.S., and Roche has a roval may be contingent of sly treated with a RET inhi id cancer and RET fusion- wan.	and Taiwan. leukemia. Received marketing hatological neoplasm or mast cell nutations. Received conditional ing the PDGFRA D842V mutation. exclusive rights to develop and on a confirmatory trial. Received bitor. -positive thyroid cancer. Continued	1

